TNGX Q2 2022 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TNGXTango Therapeutics, Inc.

$2B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M-68.2% YoY

Gross Profit

$5M88.1% margin

Operating Income

-$25M-436.7% margin

Net Income

-$25M-430.7% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

+0.2%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$33M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$448M

Total Liabilities

$150M

Stockholders' Equity

$299M

Cash & Equivalents

$105M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$18M	-68.2%
Gross Profit	$5M	$18M	-71.3%
Operating Income	-$25M	-$5M	-453.2%
Net Income	-$25M	-$4M	-453.3%

Revenue Segments

Collaboration Revenue

$6M100%